The POLR2D antibody targets the POLR2D protein, a key subunit of RNA polymerase II (Pol II), the enzyme responsible for mRNA transcription in eukaryotes. POLR2D, also known as RPB4. forms a heterodimer with POLR2G (RPB7) and contributes to Pol II stability, transcription initiation, and stress adaptation. It plays a regulatory role in transcription elongation and termination, interacting with mRNA-processing factors and chromatin remodelers. POLR2D antibodies are essential tools for studying transcriptional mechanisms, Pol II assembly, and its dysregulation in diseases like cancer and neurodegeneration. These antibodies are widely used in techniques such as Western blotting, immunoprecipitation, and immunofluorescence to assess POLR2D expression, localization, and protein-protein interactions. Commercially available POLR2D antibodies are typically validated in knockout cell lines to ensure specificity. Research using POLR2D antibodies has highlighted its role in cellular stress responses, where POLR2D levels dynamically regulate transcription under adverse conditions. Aberrant POLR2D expression has been linked to tumor progression and chemoresistance, making it a potential biomarker or therapeutic target. Host species (e.g., rabbit, mouse) and clonal variants (monoclonal/polyclonal) offer flexibility for experimental designs. Proper validation remains critical due to Pol II's complexity and shared subunits across polymerase isoforms.